01 Keytruda by Merck

Merck ( NYSE : Mrk ) recently received FDA approval for its new immune-oncology drug Keytruda ( pembrolizumab ). The drug will cost roughly $ 12,500 per month for treatment and targets advanced melanoma that accounts for most of the deaths from skin cancer cases . Keytruda also has potential in other cancers with studies underway in lung and kidney cancer .

www . merck . com

30 January 2015